Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd, has entered into a cooperation agreement with Taizhou Mabtech Pharmaceutical Ltd, a subsidiary of Mabpharm Ltd (HKG: 2181), focusing on the molecule CMAB009. Under the terms of the deal, Simcere Zaiming has obtained exclusive commercial rights to CMAB009 in the Chinese mainland market.
CMAB009: A Promising Anti-EGFR Chimeric Monoclonal Antibody
CMAB009 is a recombinant anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody designed for the first-line treatment of metastatic colorectal cancer (mCRC) in combination with FOLFIRI. The molecule is prepared using a specific expression process that effectively avoids glycosylation modification, which is known to potentially cause hypersensitivity. The safety and efficacy of CMAB009 have been demonstrated in two completed clinical trials, showcasing its potential in the treatment of mCRC.
CMAB009’s Therapeutic Advantages and Market Prospects
Compared to currently marketed anti-EGFR antibody drugs, CMAB009 is viewed as having a significant advantage in terms of therapeutic effect for mCRC. In March 2023, Mabwell filed a marketing approval application for CMAB009 with the National Medical Products Administration in China. CMAB009 is expected to be the first domestically developed anti-EGFR monoclonal antibody (mAb) for mCRC, marking a significant milestone in the advancement of domestic pharmaceutical innovation in China.-Fineline Info & Tech
